RT Journal Article
SR Electronic
T1 Eosinophilic phenotype classification of patients with asthma and/or COPD in NOVELTY
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3705
DO 10.1183/13993003.congress-2021.PA3705
VO 58
IS suppl 65
A1 Price, David
A1 Pavord, Ian D
A1 Peres Da Costa, Keith
A1 Agustí, Alvar
A1 Anderson, Gary P
A1 Bansal, Aruna T
A1 Bel, Elisabeth H
A1 Fagerås, Malin
A1 Hughes, Rod
A1 Inoue, Hiromasa
A1 Lassi, Glenda
A1 Olaguibel, José María
A1 Papi, Alberto
A1 Rabahi, Marcelo
A1 Reddel, Helen K
A1 Rendon, Adrian
A1 Van Den Berge, Maarten
A1 Müllerová, Hana
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3705.abstract
AB Introduction: Identification of an eosinophilic (EOS) phenotype in obstructive lung disease is important for disease management. The International Severe Asthma Registry (ISAR) proposes EOS Grades, a classification based on blood eosinophil count and clinical characteristics.Aim: To describe and characterise the ISAR EOS Grades in patients with asthma and/or COPD from NOVELTY.Methods: NOVELTY (NCT02760329) is a global, observational study of patients with physician-assigned diagnosis of asthma and/or COPD. The ISAR EOS Grades classify patients as Grades 0 to 3 (Grade 0=unlikely/non-eosinophilic to Grade 3=most likely eosinophilic; figure).Results: Of 4,877 patients with available baseline data, Grade 3 was found in 29% overall and 37%, 29% and 17% of patients with asthma (N=2,605), asthma+COPD (N=630) and COPD (N=1,642), respectively. The frequency of Grade 3 increased with physician-assessed severity for asthma and asthma+COPD, but not COPD. For all diagnoses, the mean exacerbation rate in the past 12 months was higher among Grade 3 (1.02, overall) vs Grades 0–2 (0.75–0.84, overall). For asthma and asthma+COPD, but not COPD, there was greater airflow obstruction and poorer quality of life among Grade 3 vs Grades 0–2.Conclusion: ISAR-defined EOS Grade 3 was prevalent in patients with asthma and/or COPD and was associated with higher physician-assessed severity and exacerbation rate. FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3705.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).